Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Slides:

Advertisements

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Management of independent motion between multiple targets in lung cancer radiation therapy Feng Liu, PhD, An Tai, PhD, Ergun Ahunbay, PhD, Elizabeth.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy Dawn Owen, MD, PhD, Charles S. Mayo, PhD,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer Jeffrey L. Port, MD, Bhupesh Parashar,

Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality Research in Radiation Oncology.

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Dawn Owen, MD, PhD, Nadia N. Laack, MD, MSc, Charles S

Gastric perforation following stereotactic body radiation therapy of hepatic metastasis from colon cancer Matthew J. Furman, MD, Giles F. Whalen, MD,

Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree Justin M. Haseltine, BSE,

Dosimetric comparison of 3-dimensional conformal radiation therapy and intensity modulated radiation therapy and impact of setup errors in lower limb.

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Phantom Verification of AAA and Acuros Dose Calculations for Lung Cancer: Do Tumor Size and Regression Matter? Satomi Shiraishi, PhD, Luis E. Fong de.

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Joshua E. Rosen, BASc, Michelle C

A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic.

Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients Mary P. Walker, DDS, PhD, Brian Wichman, MS, An-Lin Cheng, PhD, James.

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer Xiaoying Liang, PhD, Dandan Zheng, PhD, Maria Mamalui-Hunter,

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer Katrina Woodford, Vanessa Panettieri, Trieumy Tran Le,

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

An Editorial Note: The Long Arm of Practical Radiation Oncology

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer Michael D. Hasselle, MD, Daniel.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Burnout and Resiliency in Canadian Oncology Residents: A Nationwide Resident and Program Director Survey Hannah Dahn, MD, Angela McGibbon, MD, David.

Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters John J. Cuaron, MD, Ellen D. Yorke, PhD, Amanda Foster, BA, Meier Hsu, MS,

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American.

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative.

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability Prashant Gabani, MD, Benjamin W.

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

International Thymic Malignancies Interest Group: A Way Forward

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography.

Journal of Thoracic Oncology

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Presentation transcript:

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control Niraj Mehta, MD, Christopher R. King, MD, PhD, Nzhde Agazaryan, PhD, Michael Steinberg, MD, Amanda Hua, BA, Percy Lee, MD Practical Radiation Oncology Volume 2, Issue 4, Pages 288-295 (October 2012) DOI: 10.1016/j.prro.2011.10.004 Copyright © 2012 American Society for Radiation Oncology Terms and Conditions

Figure 1 Tumor control probability as a function of the biological equivalent dose (BED) plot for the linear quadratic (LQ) model and the universal survival curve (USC) model as well as their associated least square regression fitted curves. Practical Radiation Oncology 2012 2, 288-295DOI: (10.1016/j.prro.2011.10.004) Copyright © 2012 American Society for Radiation Oncology Terms and Conditions

Figure 2 Tumor control probability as a function of the equivalent dose in 2 Gy (EQD2) and the standard effective dose (SED) – EQD2 for the universal survival curve model as well as their associated least square regression fitted curves. Practical Radiation Oncology 2012 2, 288-295DOI: (10.1016/j.prro.2011.10.004) Copyright © 2012 American Society for Radiation Oncology Terms and Conditions